EICHORCondition: Breast Cancer · Lymph Node Metastasis · Sponsor: Shantou Central Hospital
Interested? Contact the study team ↓
Breast cancer is a malignant tumor with the highest morbidity and mortality among women worldwide. Accurate staging of axillary lymph nodes is critical for metastatic assessment and decisions regarding treatment modalities in breast cancer patient. Among patients who underwent sentinel lymph node biopsy, about 70 % of the patients had negative pathological results and in other words, these 70 % of the patients received unnecessary surgery. At present, imaging and pathological diagnosis is the main measure of lymph node metastasis in breast cancer. However, limitations remained. Artificial intelligence, including deep learning and machine learning algorithms, has emerged as a possible technique, which can make a more accuracy prediction through machine-based collection, learning and processing of previous information, especially in radiology and pathology-based diagnosis. With the intensification of the concept of precision medicine and the development of non-invasive technology, the investigators intend to use the artificial intelligence technology to develop a serum and tissue-based predictive model for sentinel lymph node metastasis diagnosis combined with imaging and pathological information, providing specific, efficient and non-invasive biological indicators for the monitoring and early intervention of lymph node metastasis in patient with breast cancer. Therefore, the investigators retrospectively include serum samples from early breast cancer patients undergoing sentin…
This description comes directly from the study's public registry record.
Xiaorong Lin, Dr. · 13790891600 · clarelynn_lin@163.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Pathological diagnosis of breast cancer * No preoperative therapy including chemotherapy or endocrine therapy * No distant metastasis * Underwent mastectomy or breast-conserving surgery with sentinel lymph node biopsy * Agreed to provide preoperative peripheral blood samples * Had access to imaging, pathological and follow-up data for preoperative and postoperative evaluation of the disease Exclusion Criteria: * Neoadjuvant therapy * Presence of distant metastasis at time of diagnosis * Primary malignancies other than breast cancer * Bilateral breast cancer or previous contralateral breast cancer * Undergo modified radical surgery for breast cancer without sentinel lymph node biopsy * Incomplete pathological data and follow-up data * Pregnancy and other conditions determined by the investigator to be ineligible for inclusion in the study
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Shantou Central Hospital | Shantou, Guangdong, China | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06001528